CIGNA members: Please note that you may receive a letter in the mail stating that The Dermatology Center of Indiana is no longer in your network. This communication from CIGNA is incorrect and we would like to reassure you that we are still in network with CIGNA. We look forward to continuing to service you and your family for all your dermatology needs.

2017

Scalp Psoriasis
Sponsor: Tolmar
A Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study Comparing TOLMAR
Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension 0.005%/0.064% to
Reference Listed Drug in the Treatment of Scalp Psoriasis
Phase: 3
Start Date: 2017
End Date: 2018

Axillary Hyperhidrosis
Sponsor: Brickell Biotech
A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and
Efficacy of 5%, 10% and 15% Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects with
Axillary Hyperhidrosis
Phase: 2
Start Date: 2017
End Date: 2017

Psoriasis
Sponsor: Janssen
A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and
Safety of CNTO 1959 (Guselkumab) Delivered via a SelfDose™ Device in the Treatment of Subjects With
Moderate to Severe Plaque-type Psoriasis
Phase: 3
Start Date: 2017
End Date: 2018

Psoriasis
Sponsor: Janssen
A phase 3, Multicenter, randomized, double-blind study evaluating the comparative efficacy of CNTO
1959 (Guselkumab) and secukinmab for the treatment of Moderate to Severe Plaque-Type Psoriasis
Phase: 3
Start Date: 2017
End Date: 2018

Atopic Dermatitis
Sponsor: Incyte
A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1 % Cream-Controlled
Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults
With Atopic Dermatitis
Phase: 2
Start Date: 2017
End Date: 2018

Psoriasis
Sponsor: Ferndale
A Multicenter study of psorx lotion in subjects with moderate plaque psoriasis
Phase:
Start Date: 2017
End Date: 2018

Cutaneous Common Warts
Sponsor: Cutanea
A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and
Safety of CLS006 versus Vehicle in Subjects 12 years of age or older with Cutaneous Common Warts
12 years or older
Phase: 3
Start Date: 2017
End Date: 2018

Common Warts
Sponsor: Aclaris
A Randomized Double-Blind, Vehicle-Controlled, Parallel Group Study Of A-101 Topical Solution Applied
Once A Week In Subjects With Common Warts
Phase: 2
Start Date: 2017
End Date: 2018

Severe Acne Vulgaris
Sponsor: Foamix
A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical
Administration of FMX101 for 12 weeks in the Treatment of Moderate – to – Severe Acne Vulgaris
Phase: 3
Start Date: 2017
End Date: 2018

Moderate to Severe Atopic Dermatitis
Sponsor: Regeneron
A Randomized, Double-Blind, Placebo-Controlled Study To Investigate The Efficacy And Safety Of
Dupilumab Monotherapy In Patients ≥12 To <18 Years Of Age, With Moderate-To-Severe Atopic Dermatitis
12 To 18 Years Of Age
Phase: 3
Start Date: 2017
End Date: 2018

Facial Acne Vulgaris
Sponsor: Therapeutics
A multicenter, randomized, double-blind, vehicle-controlled, parallel group comparison study to evaluate the safety and efficacy of UHE-101 cream 1% when applied twice daily for 12 weeks in subjects with facial acne vulgaris.
Phase: 2
Start Date: 2017
End Date: 2018

Pruritus
Sponsor: Sienna
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib Ointment) in Subjects with Pruritus Associated with
Psoriasis Vulgaris
Phase: 2b
Start Date: 2017
End Date: 2018

Facial Papulopustular Rosacea
Sponsor: Foamix
A Randomized, Multicenter, Double-blind, Vehicle controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular
Rosacea (FX2016-11)
Phase:
Start Date: 2017
End Date: 2018

Plaque Psoriasis
Sponsor:
A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis
Phase:
Start Date: 2017
End Date: 2018